Thus, the real challenge in pharmaceutical inhibition is to prevent excess TGFβ signaling whilst still maintaining a basal level in order to maintain e.g., in cancer its known early-phase inhibitory effects on tumor cell proliferation and tumor growth. This evidence concerns the gene TGFB1 and cancer.